Skip to main content
. 2016 Oct 3;34(36):4323–4328. doi: 10.1200/JCO.2016.67.4184

Fig 3.

Fig 3.

Unadjusted time to tyrosine kinase inhibitor (TKI) initiation among Medicare beneficiaries with chronic myeloid leukemia by receipt of cost-sharing subsidy. (*) Difference in the number of patients at risk between time periods was less than 11 and suppressed to protect confidentiality.